Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer

By / 23/10/2023

Astellas Pharma Inc. and Seagen Inc. announced results from the Phase 3 EV-302 clinical trial for PADCEV® in combination with KEYTRUDA® versus chemotherapy.